<abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:dn="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/abstract/scopus_id/77953120317</prism:url><dc:identifier>SCOPUS_ID:77953120317</dc:identifier><eid>2-s2.0-77953120317</eid><pubmed-id>20039121</pubmed-id><prism:doi>10.1007/s10549-009-0691-8</prism:doi><dc:title>High levels of uPA and PAI-1 predict a good response to anthracyclines</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><citedby-count>21</citedby-count><prism:publicationName>Breast Cancer Research and Treatment</prism:publicationName><source-id>28766</source-id><prism:issn>01676806 15737217</prism:issn><prism:volume>121</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:startingPage>615</prism:startingPage><prism:endingPage>624</prism:endingPage><prism:pageRange>615-624</prism:pageRange><prism:coverDate>2010-06-01</prism:coverDate><openaccess>2</openaccess><openaccessFlag/><dc:creator><author seq="1" auid="6602246303"><ce:initials>S.</ce:initials><ce:indexed-name>Borstnar S.</ce:indexed-name><ce:surname>Borstnar</ce:surname><ce:given-name>Simona</ce:given-name><preferred-name><ce:initials>S.</ce:initials><ce:indexed-name>Borstnar S.</ce:indexed-name><ce:surname>Borstnar</ce:surname><ce:given-name>Simona</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/6602246303</author-url><affiliation id="60000966" href="https://api.elsevier.com/content/affiliation/affiliation_id/60000966"/></author></dc:creator><dc:description><abstract xmlns="" original="y" xml:lang="eng"><ce:para>Urokinase-type plasminogen activator (uPA) and its main inhibitor (PAI-1) were shown with level 1 evidence to be prognostic factors for primary breast cancer. Our preliminary retrospective study on a cohort of 1,220 consecutive patients hinted that uPA and PAI-1 could also serve as predictive factors for systemic therapy, namely that patients with high levels of the two markers benefit much more from anthracycline-based chemotherapy than patients with low levels of the two markers. The latter could equally well be treated with less toxic CMF-based chemotherapy (cyclophosphamide, methotrexate, and fluorouracil). The retrospective study, however, suffered from severely uneven patient and tumor characteristics as the patients were treated per institutional guidelines valid at the time and were not randomized between the anthracycline and CMF arms. In the present paper, we attempted to remedy this shortcoming and recheck our previous observations on more balanced data. To this end we employed a custom-made computer algorithm that selected 180 patients out of a total of 1,220 patients such that we obtained very well balanced anthracycline and CMF arms according to patient and tumor characteristics. Moreover, the low and high uPA/PAI-1 subgroups within both arms were also completely balanced. The algorithm in a way created a similar setting to that of a randomized study at the expense of greatly reducing the number of patients included into the study. In this setting, we observed the 3-year disease-free survival (DFS) in all four subgroups (according to treatment and levels of markers: both uPA and PAI-1 low versus one or both high). We report that the 3-year DFS in the CMF arm differed significantly: 87.1% for patients with low levels of markers versus 77.0% for patients with high levels of markers (P = 0.044, HR = 2.81, 95% CI = 0.98-8.04). On the other hand, the 3-year DFS in the anthracycline arm did not differ much between the two marker level subgroups: 85.2% for patients with low levels of markers versus 81.8% for patients with high levels of markers. Our observation points out that worse prognosis correlated to high uPA and PAI-1 levels can be reversed by treatment efficacy achieved through anthracycline-based chemotherapy. Based on this observation, we hypothesize that uPA/PAI-1 combination could be predictive for response to systemic therapy. © Springer Science+Business Media, LLC. 2009.</ce:para></abstract></dc:description><link href="https://api.elsevier.com/content/abstract/scopus_id/77953120317" rel="self"/><link href="https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&amp;scp=77953120317&amp;origin=inward" rel="scopus"/><link href="https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&amp;scp=77953120317&amp;origin=inward" rel="scopus-citedby"/></coredata><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"><affilname>Bolnišnica Golnik</affilname><affiliation-city>Golnik</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="60031106" href="https://api.elsevier.com/content/affiliation/affiliation_id/60031106"><affilname>University of Ljubljana</affilname><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="60000966" href="https://api.elsevier.com/content/affiliation/affiliation_id/60000966"><affilname>Onkološki inštitut Ljubljana</affilname><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><authors><author seq="1" auid="6602246303"><ce:initials>S.</ce:initials><ce:indexed-name>Borstnar S.</ce:indexed-name><ce:surname>Borstnar</ce:surname><ce:given-name>Simona</ce:given-name><preferred-name><ce:initials>S.</ce:initials><ce:indexed-name>Borstnar S.</ce:indexed-name><ce:surname>Borstnar</ce:surname><ce:given-name>Simona</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/6602246303</author-url><affiliation id="60000966" href="https://api.elsevier.com/content/affiliation/affiliation_id/60000966"/></author><author seq="2" auid="55883901600"><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name><preferred-name><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/55883901600</author-url><affiliation id="60000966" href="https://api.elsevier.com/content/affiliation/affiliation_id/60000966"/></author><author seq="3" auid="36495158300"><ce:initials>B.</ce:initials><ce:indexed-name>Mozina B.</ce:indexed-name><ce:surname>Mozina</ce:surname><ce:given-name>Barbara</ce:given-name><preferred-name><ce:initials>B.</ce:initials><ce:indexed-name>Mozina B.</ce:indexed-name><ce:surname>Mozina</ce:surname><ce:given-name>Barbara</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/36495158300</author-url><affiliation id="60031106" href="https://api.elsevier.com/content/affiliation/affiliation_id/60031106"/></author><author seq="4" auid="7004393140"><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>Tanja</ce:given-name><preferred-name><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>Tanja</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/7004393140</author-url><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"/></author></authors><language xml:lang="eng"/><authkeywords><author-keyword>Anthracycline-based chemotherapy</author-keyword><author-keyword>Balancing patients' and tumor characteristics</author-keyword><author-keyword>Breast cancer</author-keyword><author-keyword>PAI-1</author-keyword><author-keyword>Predictive value</author-keyword><author-keyword>uPA</author-keyword></authkeywords><idxterms/><subject-areas><subject-area code="2730" abbrev="MEDI">Oncology</subject-area><subject-area code="1306" abbrev="BIOC">Cancer Research</subject-area></subject-areas><item xmlns=""><xocs:meta><xocs:funding-list has-funding-info="1" pui-match="primary"><xocs:funding-addon-generated-timestamp>2017-11-11T05:33:10.325Z</xocs:funding-addon-generated-timestamp></xocs:funding-list></xocs:meta><ait:process-info><ait:date-delivered year="2017" month="08" day="21" timestamp="2017-08-21T00:20:17.000017-04:00"/><ait:date-sort year="2010" month="06" day="01"/><ait:status type="core" state="update" stage="S300"/></ait:process-info><bibrecord><item-info><copyright type="Elsevier">Copyright 2011 Elsevier B.V., All rights reserved.</copyright><copyright type="Medline Descriptors">MEDLINE® is the source for the MeSH terms of this document.</copyright><itemidlist><ce:doi>10.1007/s10549-009-0691-8</ce:doi><itemid idtype="PUI">50748340</itemid><itemid idtype="EMBASE">2010313042</itemid><itemid idtype="CABS">2010169173</itemid><itemid idtype="MEDL">20039121</itemid><itemid idtype="SCP">77953120317</itemid><itemid idtype="SGR">77953120317</itemid></itemidlist><history><date-created year="2009" month="12" day="29"/></history><dbcollection>EMBASE</dbcollection><dbcollection>CABS</dbcollection><dbcollection>MEDL</dbcollection><dbcollection>Scopusbase</dbcollection></item-info><head><citation-info><citation-type code="ar"/><citation-language xml:lang="eng" language="English"/><abstract-language xml:lang="eng" language="English"/><author-keywords><author-keyword>Anthracycline-based chemotherapy</author-keyword><author-keyword>Balancing patients' and tumor characteristics</author-keyword><author-keyword>Breast cancer</author-keyword><author-keyword>PAI-1</author-keyword><author-keyword>Predictive value</author-keyword><author-keyword>uPA</author-keyword></author-keywords></citation-info><citation-title><titletext xml:lang="eng" original="y" language="English">High levels of uPA and PAI-1 predict a good response to anthracyclines</titletext></citation-title><author-group><author auid="6602246303" seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Borstnar S.</ce:indexed-name><ce:surname>Borstnar</ce:surname><ce:given-name>Simona</ce:given-name><preferred-name><ce:initials>S.</ce:initials><ce:indexed-name>Borstnar S.</ce:indexed-name><ce:surname>Borstnar</ce:surname><ce:given-name>Simona</ce:given-name></preferred-name></author><author auid="55883901600" seq="2"><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name><preferred-name><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name></preferred-name></author><affiliation afid="60000966" country="svn"><organization>Institute of Oncology</organization><address-part>Zaloska 2</address-part><city-group>Ljubljana 1000</city-group><affiliation-id afid="60000966"/><country>Slovenia</country></affiliation></author-group><author-group><author auid="36495158300" seq="3"><ce:initials>B.</ce:initials><ce:indexed-name>Mozina B.</ce:indexed-name><ce:surname>Mozina</ce:surname><ce:given-name>Barbara</ce:given-name><preferred-name><ce:initials>B.</ce:initials><ce:indexed-name>Mozina B.</ce:indexed-name><ce:surname>Mozina</ce:surname><ce:given-name>Barbara</ce:given-name></preferred-name></author><affiliation afid="60031106" dptid="104580932" country="svn"><organization>Faculty of Computer and Information Science</organization><organization>Artificial Intelligence Laboratory</organization><organization>University of Ljubljana</organization><address-part>Trzaska 25</address-part><city-group>Ljubljana 1000</city-group><affiliation-id afid="60031106" dptid="104580932"/><country>Slovenia</country></affiliation></author-group><author-group><author auid="7004393140" seq="4"><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>Tanja</ce:given-name><preferred-name><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>Tanja</ce:given-name></preferred-name></author><affiliation afid="60078312" country="svn"><organization>University Clinic Golnik</organization><city-group>Golnik 4204</city-group><affiliation-id afid="60078312"/><country>Slovenia</country></affiliation></author-group><correspondence><person><ce:initials>S.</ce:initials><ce:indexed-name>Borstnar S.</ce:indexed-name><ce:surname>Borstnar</ce:surname></person><affiliation country="svn"><organization>Institute of Oncology</organization><address-part>Zaloska 2</address-part><city-group>Ljubljana 1000</city-group><country>Slovenia</country></affiliation></correspondence><abstracts><abstract original="y" xml:lang="eng"><ce:para>Urokinase-type plasminogen activator (uPA) and its main inhibitor (PAI-1) were shown with level 1 evidence to be prognostic factors for primary breast cancer. Our preliminary retrospective study on a cohort of 1,220 consecutive patients hinted that uPA and PAI-1 could also serve as predictive factors for systemic therapy, namely that patients with high levels of the two markers benefit much more from anthracycline-based chemotherapy than patients with low levels of the two markers. The latter could equally well be treated with less toxic CMF-based chemotherapy (cyclophosphamide, methotrexate, and fluorouracil). The retrospective study, however, suffered from severely uneven patient and tumor characteristics as the patients were treated per institutional guidelines valid at the time and were not randomized between the anthracycline and CMF arms. In the present paper, we attempted to remedy this shortcoming and recheck our previous observations on more balanced data. To this end we employed a custom-made computer algorithm that selected 180 patients out of a total of 1,220 patients such that we obtained very well balanced anthracycline and CMF arms according to patient and tumor characteristics. Moreover, the low and high uPA/PAI-1 subgroups within both arms were also completely balanced. The algorithm in a way created a similar setting to that of a randomized study at the expense of greatly reducing the number of patients included into the study. In this setting, we observed the 3-year disease-free survival (DFS) in all four subgroups (according to treatment and levels of markers: both uPA and PAI-1 low versus one or both high). We report that the 3-year DFS in the CMF arm differed significantly: 87.1% for patients with low levels of markers versus 77.0% for patients with high levels of markers (P = 0.044, HR = 2.81, 95% CI = 0.98-8.04). On the other hand, the 3-year DFS in the anthracycline arm did not differ much between the two marker level subgroups: 85.2% for patients with low levels of markers versus 81.8% for patients with high levels of markers. Our observation points out that worse prognosis correlated to high uPA and PAI-1 levels can be reversed by treatment efficacy achieved through anthracycline-based chemotherapy. Based on this observation, we hypothesize that uPA/PAI-1 combination could be predictive for response to systemic therapy. © Springer Science+Business Media, LLC. 2009.</ce:para></abstract></abstracts><source srcid="28766" type="j" country="usa"><sourcetitle>Breast Cancer Research and Treatment</sourcetitle><sourcetitle-abbrev>Breast Cancer Res. Treat.</sourcetitle-abbrev><issn type="print">01676806</issn><issn type="electronic">15737217</issn><codencode>BCTRD</codencode><volisspag><voliss volume="121" issue="3"/><pagerange first="615" last="624"/></volisspag><publicationyear first="2010"/><publicationdate><year>2010</year><month>06</month><date-text xfab-added="true">June 2010</date-text></publicationdate></source><enhancement><classificationgroup><classifications type="CABSCLASS"><classification> <classification-code>87.4.1.4</classification-code> <classification-description>CANCER RESEARCH; TREATMENT; Chemotherapy; Anthracyclines and other antibiotics</classification-description> </classification><classification> <classification-code>87.5.11</classification-code> <classification-description>CANCER RESEARCH; CLINICAL INVESTIGATIONS BY ORGAN SITE; Breast</classification-description> </classification></classifications><classifications type="EMCLASS"><classification> <classification-code>16.19</classification-code> <classification-description>Cancer; BREAST</classification-description> </classification><classification> <classification-code>16.4.1</classification-code> <classification-description>Cancer; TREATMENT AND PATIENT MANAGEMENT; Chemotherapy</classification-description> </classification><classification> <classification-code>29.2</classification-code> <classification-description>Clinical and Experimental Biochemistry; ANALYSIS</classification-description> </classification><classification> <classification-code>29.5</classification-code> <classification-description>Clinical and Experimental Biochemistry; PROTEIN STRUCTURE AND FUNCTION</classification-description> </classification><classification> <classification-code>37</classification-code> <classification-description>Drug Literature Index</classification-description> </classification></classifications><classifications type="ASJC"><classification>2730</classification><classification>1306</classification></classifications><classifications type="SUBJABBR"><classification>MEDI</classification><classification>BIOC</classification></classifications></classificationgroup><chemicalgroup><chemicals source="esbd"><chemical><chemical-name>cyclophosphamide</chemical-name><cas-registry-number>50-18-0</cas-registry-number></chemical><chemical><chemical-name>fluorouracil</chemical-name><cas-registry-number>51-21-8</cas-registry-number></chemical><chemical><chemical-name>methotrexate</chemical-name><cas-registry-number>15475-56-6</cas-registry-number><cas-registry-number>59-05-2</cas-registry-number><cas-registry-number>7413-34-5</cas-registry-number></chemical><chemical><chemical-name>plasminogen activator inhibitor 1</chemical-name><cas-registry-number>140208-23-7</cas-registry-number></chemical><chemical><chemical-name>urokinase</chemical-name><cas-registry-number>139639-24-0</cas-registry-number></chemical></chemicals><chemicals source="nlm"><chemical><chemical-name>Anthracyclines</chemical-name><cas-registry-number>0</cas-registry-number></chemical><chemical><chemical-name>Antibiotics, Antineoplastic</chemical-name><cas-registry-number>0</cas-registry-number></chemical><chemical><chemical-name>Cyclophosphamide</chemical-name><cas-registry-number>50-18-0</cas-registry-number></chemical><chemical><chemical-name>Fluorouracil</chemical-name><cas-registry-number>51-21-8</cas-registry-number></chemical><chemical><chemical-name>Methotrexate</chemical-name><cas-registry-number>59-05-2</cas-registry-number></chemical><chemical><chemical-name>Plasminogen Activator Inhibitor 1</chemical-name><cas-registry-number>0</cas-registry-number></chemical><chemical><chemical-name>Tumor Markers, Biological</chemical-name><cas-registry-number>0</cas-registry-number></chemical><chemical><chemical-name>Urokinase-Type Plasminogen Activator</chemical-name><cas-registry-number>3.4.21.73</cas-registry-number></chemical></chemicals></chemicalgroup></enhancement></head><tail><bibliography refcount="33"><reference id="1"><ref-info><ref-title><ref-titletext>Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">19344364880</itemid></refd-itemidlist><ref-sourcetitle>Lancet</ref-sourcetitle><ref-publicationyear first="2005"/><ref-volisspag><voliss volume="365" issue="9472"/><pagerange first="1687" last="1717"/></ref-volisspag><ref-text>DOI 10.1016/S0140-6736(05)66544-0, PII S0140673605665440</ref-text></ref-info><ref-fulltext>Early Breast Cancer Trialists Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717 (Pubitemid 40719106)</ref-fulltext></reference><reference id="2"><ref-info><ref-title><ref-titletext>HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">38049103907</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.</ce:initials><ce:indexed-name>Gennari A.</ce:indexed-name><ce:surname>Gennari</ce:surname></author><author seq="2"><ce:initials>M.P.</ce:initials><ce:indexed-name>Sormani M.P.</ce:indexed-name><ce:surname>Sormani</ce:surname></author><author seq="3"><ce:initials>P.</ce:initials><ce:indexed-name>Pronzato P.</ce:indexed-name><ce:surname>Pronzato</ce:surname></author><author seq="4"><ce:initials>M.</ce:initials><ce:indexed-name>Puntoni M.</ce:indexed-name><ce:surname>Puntoni</ce:surname></author><author seq="5"><ce:initials>M.</ce:initials><ce:indexed-name>Colozza M.</ce:indexed-name><ce:surname>Colozza</ce:surname></author><author seq="6"><ce:initials>U.</ce:initials><ce:indexed-name>Pfeffer U.</ce:indexed-name><ce:surname>Pfeffer</ce:surname></author><author seq="7"><ce:initials>P.</ce:initials><ce:indexed-name>Bruzzi P.</ce:indexed-name><ce:surname>Bruzzi</ce:surname></author></ref-authors><ref-sourcetitle>Journal of the National Cancer Institute</ref-sourcetitle><ref-publicationyear first="2008"/><ref-volisspag><voliss volume="100" issue="1"/><pagerange first="14" last="20"/></ref-volisspag><ref-text>DOI 10.1093/jnci/djm252</ref-text></ref-info><ref-fulltext>Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, Bruzzi P (2008) HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 100(1): 14-20 (Pubitemid 351767337)</ref-fulltext></reference><reference id="3"><ref-info><ref-title><ref-titletext>HER-2 and topoisomerase II as predictors of response to chemotherapy</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">39149126730</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>K.I.</ce:initials><ce:indexed-name>Pritchard K.I.</ce:indexed-name><ce:surname>Pritchard</ce:surname></author><author seq="2"><ce:initials>H.</ce:initials><ce:indexed-name>Messersmith H.</ce:indexed-name><ce:surname>Messersmith</ce:surname></author><author seq="3"><ce:initials>L.</ce:initials><ce:indexed-name>Elavathil L.</ce:indexed-name><ce:surname>Elavathil</ce:surname></author><author seq="4"><ce:initials>M.</ce:initials><ce:indexed-name>Trudeau M.</ce:indexed-name><ce:surname>Trudeau</ce:surname></author><author seq="5"><ce:initials>F.</ce:initials><ce:indexed-name>O'Malley F.</ce:indexed-name><ce:surname>O'Malley</ce:surname></author><author seq="6"><ce:initials>B.</ce:initials><ce:indexed-name>Dhesy-Thind B.</ce:indexed-name><ce:surname>Dhesy-Thind</ce:surname></author></ref-authors><ref-sourcetitle>Journal of Clinical Oncology</ref-sourcetitle><ref-publicationyear first="2008"/><ref-volisspag><voliss volume="26" issue="5"/><pagerange first="736" last="744"/></ref-volisspag><ref-website><ce:e-address type="url">http://jco.ascopubs.org/cgi/reprint/26/5/736</ce:e-address></ref-website><ref-text>DOI 10.1200/JCO.2007.15.4716</ref-text></ref-info><ref-fulltext>Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O'Malley F, Dhesy-Thind B (2008) HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 26(5):736-744 (Pubitemid 351264386)</ref-fulltext></reference><reference id="4"><ref-info><ref-title><ref-titletext>Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA. 5)</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">33749622561</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>F.P.</ce:initials><ce:indexed-name>O'Malley F.P.</ce:indexed-name><ce:surname>O'Malley</ce:surname></author><author seq="2"><ce:initials>S.</ce:initials><ce:indexed-name>Chia S.</ce:indexed-name><ce:surname>Chia</ce:surname></author><author seq="3"><ce:initials>D.</ce:initials><ce:indexed-name>Tu D.</ce:indexed-name><ce:surname>Tu</ce:surname></author><author seq="4"><ce:initials>L.E.</ce:initials><ce:indexed-name>Shepherd L.E.</ce:indexed-name><ce:surname>Shepherd</ce:surname></author><author seq="5"><ce:initials>M.N.</ce:initials><ce:indexed-name>Levine M.N.</ce:indexed-name><ce:surname>Levine</ce:surname></author><author seq="6"><ce:initials>D.</ce:initials><ce:indexed-name>Huntsman D.</ce:indexed-name><ce:surname>Huntsman</ce:surname></author><author seq="7"><ce:initials>V.H.</ce:initials><ce:indexed-name>Bramwell V.H.</ce:indexed-name><ce:surname>Bramwell</ce:surname></author><author seq="8"><ce:initials>I.</ce:initials><ce:indexed-name>Andrulis I.</ce:indexed-name><ce:surname>Andrulis</ce:surname></author><author seq="9"><ce:initials>K.I.</ce:initials><ce:indexed-name>Pritchard K.I.</ce:indexed-name><ce:surname>Pritchard</ce:surname></author></ref-authors><ref-sourcetitle>J Clin Oncol</ref-sourcetitle><ref-publicationyear first="2006"/><ref-volisspag><voliss volume="24" issue="SUPPL."/><pagerange first="11"/></ref-volisspag><ref-text>abstr 533</ref-text></ref-info><ref-fulltext>O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman D, Bramwell VH, Andrulis I, Pritchard KI (2006) Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA. 5). J Clin Oncol 24:11s (suppl; abstr 533)</ref-fulltext></reference><reference id="5"><ref-info><ref-title><ref-titletext>The urokinase-type plasminogen activator system in cancer metastasis: A review</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0030788411</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>P.A.</ce:initials><ce:indexed-name>Andreasen P.A.</ce:indexed-name><ce:surname>Andreasen</ce:surname></author><author seq="2"><ce:initials>L.</ce:initials><ce:indexed-name>Kjoller L.</ce:indexed-name><ce:surname>Kjoller</ce:surname></author><author seq="3"><ce:initials>L.</ce:initials><ce:indexed-name>Christensen L.</ce:indexed-name><ce:surname>Christensen</ce:surname></author><author seq="4"><ce:initials>M.J.</ce:initials><ce:indexed-name>Duffy M.J.</ce:indexed-name><ce:surname>Duffy</ce:surname></author></ref-authors><ref-sourcetitle>International Journal of Cancer</ref-sourcetitle><ref-publicationyear first="1997"/><ref-volisspag><voliss volume="72" issue="1"/><pagerange first="1" last="22"/></ref-volisspag><ref-text>DOI 10.1002/(SICI)1097-0215(19970703)72:1&lt;1::AID-IJC1&gt;3.0.CO;2-Z</ref-text></ref-info><ref-fulltext>Andreasen PA, Kjøller L, Christensen L, Duffy MJ (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72:1-22 (Pubitemid 27314632)</ref-fulltext></reference><reference id="6"><ref-info><ref-title><ref-titletext>Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for therapy</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0030857717</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Schmitt M.</ce:indexed-name><ce:surname>Schmitt</ce:surname></author><author seq="2"><ce:initials>N.</ce:initials><ce:indexed-name>Harbeck N.</ce:indexed-name><ce:surname>Harbeck</ce:surname></author><author seq="3"><ce:initials>C.</ce:initials><ce:indexed-name>Thomssen C.</ce:indexed-name><ce:surname>Thomssen</ce:surname></author><author seq="4"><ce:initials>O.</ce:initials><ce:indexed-name>Wilhelm O.</ce:indexed-name><ce:surname>Wilhelm</ce:surname></author><author seq="5"><ce:initials>V.</ce:initials><ce:indexed-name>Magdolen V.</ce:indexed-name><ce:surname>Magdolen</ce:surname></author><author seq="6"><ce:initials>U.</ce:initials><ce:indexed-name>Reuning U.</ce:indexed-name><ce:surname>Reuning</ce:surname></author><author seq="7"><ce:initials>K.</ce:initials><ce:indexed-name>Ulm K.</ce:indexed-name><ce:surname>Ulm</ce:surname></author><author seq="8"><ce:initials>H.</ce:initials><ce:indexed-name>Hofler H.</ce:indexed-name><ce:surname>Hofler</ce:surname></author><author seq="9"><ce:initials>F.</ce:initials><ce:indexed-name>Janicke F.</ce:indexed-name><ce:surname>Janicke</ce:surname></author><author seq="10"><ce:initials>H.</ce:initials><ce:indexed-name>Graeff H.</ce:indexed-name><ce:surname>Graeff</ce:surname></author></ref-authors><ref-sourcetitle>Thrombosis and Haemostasis</ref-sourcetitle><ref-publicationyear first="1997"/><ref-volisspag><voliss volume="78" issue="1"/><pagerange first="285" last="296"/></ref-volisspag></ref-info><ref-fulltext>Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, Ulm K, Höfler H, Jänicke F, Graeff H (1997) Clinical impact of the plasminogen activation system in tumor invasion and metastases: prognostic relevance and target for therapy. Tromb Haemostasis 78:285-296 (Pubitemid 27289256)</ref-fulltext></reference><reference id="7"><ref-info><ref-title><ref-titletext>Urokinase plasminogen activator: A prognostic marker in multiple types of cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0033026635</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.J.</ce:initials><ce:indexed-name>Duffy M.J.</ce:indexed-name><ce:surname>Duffy</ce:surname></author><author seq="2"><ce:initials>T.M.</ce:initials><ce:indexed-name>Maguire T.M.</ce:indexed-name><ce:surname>Maguire</ce:surname></author><author seq="3"><ce:initials>E.W.</ce:initials><ce:indexed-name>Mcdermott E.W.</ce:indexed-name><ce:surname>Mcdermott</ce:surname></author><author seq="4"><ce:initials>N.</ce:initials><ce:indexed-name>O'Higgins N.</ce:indexed-name><ce:surname>O'Higgins</ce:surname></author></ref-authors><ref-sourcetitle>Journal of Surgical Oncology</ref-sourcetitle><ref-publicationyear first="1999"/><ref-volisspag><voliss volume="71" issue="2"/><pagerange first="130" last="135"/></ref-volisspag><ref-text>DOI 10.1002/(SICI)1096-9098(199906)71:2&lt;130::AID-JSO14&gt;3.0.CO;2-9</ref-text></ref-info><ref-fulltext>Duffy MJ, Maguire T, McDermott EW, O'Higgins N (1999) Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol 71:130-135 (Pubitemid 29288493)</ref-fulltext></reference><reference id="8"><ref-info><ref-title><ref-titletext>Clinical relevance of the urokinase plasminogen activator system in breast cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0033003666</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.P.</ce:initials><ce:indexed-name>Look M.P.</ce:indexed-name><ce:surname>Look</ce:surname></author><author seq="2"><ce:initials>J.A.</ce:initials><ce:indexed-name>Foekens J.A.</ce:indexed-name><ce:surname>Foekens</ce:surname></author></ref-authors><ref-sourcetitle>APMIS</ref-sourcetitle><ref-publicationyear first="2000"/><ref-volisspag><voliss volume="107" issue="150"/><pagerange first="159"/></ref-volisspag></ref-info><ref-fulltext>Look MP, Foekens JA (2000) Clinical relevance of the urokinase plasminogen activator system in breast cancer, APMIS 107:150 159</ref-fulltext></reference><reference id="9"><ref-info><ref-title><ref-titletext>Prognostic value of plasminogen activator inhibitors in breast cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0035986046</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Borstnar S.</ce:indexed-name><ce:surname>Borstnar</ce:surname></author><author seq="2"><ce:initials>I.</ce:initials><ce:indexed-name>Vrhovec I.</ce:indexed-name><ce:surname>Vrhovec</ce:surname></author><author seq="3"><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname></author></ref-authors><ref-sourcetitle>International Journal of Biological Markers</ref-sourcetitle><ref-publicationyear first="2002"/><ref-volisspag><voliss volume="17" issue="2"/><pagerange first="96" last="103"/></ref-volisspag></ref-info><ref-fulltext>Borstnar S, Vrhovec I, Cufer T (2002) Prognostic value of plasminogen activator inhibitors in breast cancer. Int J Biol Markers 17(2):96-103 (Pubitemid 34873794)</ref-fulltext></reference><reference id="10"><ref-info><ref-title><ref-titletext>Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0036348199</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Borstnar S.</ce:indexed-name><ce:surname>Borstnar</ce:surname></author><author seq="2"><ce:initials>I.</ce:initials><ce:indexed-name>Vrhovec I.</ce:indexed-name><ce:surname>Vrhovec</ce:surname></author><author seq="3"><ce:initials>B.</ce:initials><ce:indexed-name>Svetic B.</ce:indexed-name><ce:surname>Svetic</ce:surname></author><author seq="4"><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname></author></ref-authors><ref-sourcetitle>Clin Breast Cancer</ref-sourcetitle><ref-publicationyear first="2002"/><ref-volisspag><voliss volume="3" issue="2"/><pagerange first="138" last="146"/></ref-volisspag></ref-info><ref-fulltext>Borstnar S, Vrhovec I, Svetic B, Cufer T (2002) Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients. Clin Breast Cancer 3(2): 138-146</ref-fulltext></reference><reference id="11"><ref-info><ref-title><ref-titletext>Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable breast cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0042701433</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname></author><author seq="2"><ce:initials>S.</ce:initials><ce:indexed-name>Borstnar S.</ce:indexed-name><ce:surname>Borstnar</ce:surname></author><author seq="3"><ce:initials>I.</ce:initials><ce:indexed-name>Vrhovec I.</ce:indexed-name><ce:surname>Vrhovec</ce:surname></author></ref-authors><ref-sourcetitle>International Journal of Biological Markers</ref-sourcetitle><ref-publicationyear first="2003"/><ref-volisspag><voliss volume="18" issue="2"/><pagerange first="106" last="115"/></ref-volisspag></ref-info><ref-fulltext>Cufer T, Borstnar S, Vrhovec I (2003) Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable breast cancer. Int J Biol Markers 18(2): 106-115 (Pubitemid 38220138)</ref-fulltext></reference><reference id="12"><ref-info><ref-title><ref-titletext>Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0037116616</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.P.</ce:initials><ce:indexed-name>Look M.P.</ce:indexed-name><ce:surname>Look</ce:surname></author><author seq="2"><ce:initials>W.L.</ce:initials><ce:indexed-name>Van Putten W.L.</ce:indexed-name><ce:surname>Van Putten</ce:surname></author><author seq="3"><ce:initials>M.J.</ce:initials><ce:indexed-name>Duffy M.J.</ce:indexed-name><ce:surname>Duffy</ce:surname></author><author seq="4"><ce:initials>N.</ce:initials><ce:indexed-name>Harbeck N.</ce:indexed-name><ce:surname>Harbeck</ce:surname></author><author seq="5"><ce:initials>I.J.</ce:initials><ce:indexed-name>Christensen I.J.</ce:indexed-name><ce:surname>Christensen</ce:surname></author><author seq="6"><ce:initials>C.</ce:initials><ce:indexed-name>Thomssen C.</ce:indexed-name><ce:surname>Thomssen</ce:surname></author><author seq="7"><ce:initials>R.</ce:initials><ce:indexed-name>Kates R.</ce:indexed-name><ce:surname>Kates</ce:surname></author><author seq="8"><ce:initials>F.</ce:initials><ce:indexed-name>Spyratos F.</ce:indexed-name><ce:surname>Spyratos</ce:surname></author><author seq="9"><ce:initials>M.</ce:initials><ce:indexed-name>Ferno M.</ce:indexed-name><ce:surname>Fernö</ce:surname></author><author seq="10"><ce:initials>S.</ce:initials><ce:indexed-name>Eppenberger-Castori S.</ce:indexed-name><ce:surname>Eppenberger-Castori</ce:surname></author><author seq="11"><ce:initials>C.G.</ce:initials><ce:indexed-name>Sweep C.G.</ce:indexed-name><ce:surname>Sweep</ce:surname></author><author seq="12"><ce:initials>K.</ce:initials><ce:indexed-name>Ulm K.</ce:indexed-name><ce:surname>Ulm</ce:surname></author><author seq="13"><ce:initials>J.P.</ce:initials><ce:indexed-name>Peyrat J.P.</ce:indexed-name><ce:surname>Peyrat</ce:surname></author><author seq="14"><ce:initials>P.M.</ce:initials><ce:indexed-name>Martin P.M.</ce:indexed-name><ce:surname>Martin</ce:surname></author><author seq="15"><ce:initials>H.</ce:initials><ce:indexed-name>Magdelenat H.</ce:indexed-name><ce:surname>Magdelenat</ce:surname></author><author seq="16"><ce:initials>N.</ce:initials><ce:indexed-name>Brunner N.</ce:indexed-name><ce:surname>Brünner</ce:surname></author><author seq="17"><ce:initials>C.</ce:initials><ce:indexed-name>Duggan C.</ce:indexed-name><ce:surname>Duggan</ce:surname></author><author seq="18"><ce:initials>B.W.</ce:initials><ce:indexed-name>Lisboa B.W.</ce:indexed-name><ce:surname>Lisboa</ce:surname></author><author seq="19"><ce:initials>P.O.</ce:initials><ce:indexed-name>Bendahl P.O.</ce:indexed-name><ce:surname>Bendahl</ce:surname></author><author seq="20"><ce:initials>V.</ce:initials><ce:indexed-name>Quillien V.</ce:indexed-name><ce:surname>Quillien</ce:surname></author><author seq="21"><ce:initials>A.</ce:initials><ce:indexed-name>Daver A.</ce:indexed-name><ce:surname>Daver</ce:surname></author><author seq="22"><ce:initials>G.</ce:initials><ce:indexed-name>Ricolleau G.</ce:indexed-name><ce:surname>Ricolleau</ce:surname></author><author seq="23"><ce:initials>M.E.</ce:initials><ce:indexed-name>Meijer-van Gelder M.E.</ce:indexed-name><ce:surname>Meijer-van Gelder</ce:surname></author><author seq="24"><ce:initials>P.</ce:initials><ce:indexed-name>Manders P.</ce:indexed-name><ce:surname>Manders</ce:surname></author><author seq="25"><ce:initials>W.E.</ce:initials><ce:indexed-name>Fiets W.E.</ce:indexed-name><ce:surname>Fiets</ce:surname></author><author seq="26"><ce:initials>Ma.</ce:initials><ce:indexed-name>Blankenstein Ma.</ce:indexed-name><ce:surname>Blankenstein</ce:surname></author><author seq="27"><ce:initials>P.</ce:initials><ce:indexed-name>Broet P.</ce:indexed-name><ce:surname>Broët</ce:surname></author><author seq="28"><ce:initials>S.</ce:initials><ce:indexed-name>Romain S.</ce:indexed-name><ce:surname>Romain</ce:surname></author><author seq="29"><ce:initials>G.</ce:initials><ce:indexed-name>Daxenbichler G.</ce:indexed-name><ce:surname>Daxenbichler</ce:surname></author><author seq="30"><ce:initials>G.</ce:initials><ce:indexed-name>Windbichler G.</ce:indexed-name><ce:surname>Windbichler</ce:surname></author><author seq="31"><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname></author><author seq="32"><ce:initials>S.</ce:initials><ce:indexed-name>Borstnar S.</ce:indexed-name><ce:surname>Borstnar</ce:surname></author><author seq="33"><ce:initials>W.</ce:initials><ce:indexed-name>Kueng W.</ce:indexed-name><ce:surname>Kueng</ce:surname></author><author seq="34"><ce:initials>L.V.</ce:initials><ce:indexed-name>Beex L.V.</ce:indexed-name><ce:surname>Beex</ce:surname></author><author seq="35"><ce:initials>J.G.</ce:initials><ce:indexed-name>Klijn J.G.</ce:indexed-name><ce:surname>Klijn</ce:surname></author><author seq="36"><ce:initials>N.</ce:initials><ce:indexed-name>O'Higgins N.</ce:indexed-name><ce:surname>O'Higgins</ce:surname></author><author seq="37"><ce:initials>U.</ce:initials><ce:indexed-name>Eppenberger U.</ce:indexed-name><ce:surname>Eppenberger</ce:surname></author><author seq="38"><ce:initials>F.</ce:initials><ce:indexed-name>Janicke F.</ce:indexed-name><ce:surname>Jänicke</ce:surname></author><author seq="39"><ce:initials>M.</ce:initials><ce:indexed-name>Schmitt M.</ce:indexed-name><ce:surname>Schmitt</ce:surname></author><author seq="40"><ce:initials>J.A.</ce:initials><ce:indexed-name>Foekens J.A.</ce:indexed-name><ce:surname>Foekens</ce:surname></author></ref-authors><ref-sourcetitle>J Natl Cancer Inst</ref-sourcetitle><ref-publicationyear first="2002"/><ref-volisspag><voliss volume="94" issue="2"/><pagerange first="116" last="128"/></ref-volisspag></ref-info><ref-fulltext>Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fernö M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brünner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broët P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn JG, O'Higgins N, Eppenberger U, Jänicke F, Schmitt M, Foekens JA (2002) Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94(2): 116-128</ref-fulltext></reference><reference id="13"><ref-info><ref-title><ref-titletext>Randomized adjuvant chemotherapy trial in high-risk lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0035918882</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>F.</ce:initials><ce:indexed-name>Janicke F.</ce:indexed-name><ce:surname>Jänicke</ce:surname></author><author seq="2"><ce:initials>A.</ce:initials><ce:indexed-name>Prechtl A.</ce:indexed-name><ce:surname>Prechtl</ce:surname></author><author seq="3"><ce:initials>C.</ce:initials><ce:indexed-name>Thomssen C.</ce:indexed-name><ce:surname>Thomssen</ce:surname></author><author seq="4"><ce:initials>N.</ce:initials><ce:indexed-name>Harbeck N.</ce:indexed-name><ce:surname>Harbeck</ce:surname></author><author seq="5"><ce:initials>C.</ce:initials><ce:indexed-name>Meisner C.</ce:indexed-name><ce:surname>Meisner</ce:surname></author><author seq="6"><ce:initials>M.</ce:initials><ce:indexed-name>Untch M.</ce:indexed-name><ce:surname>Untch</ce:surname></author><author seq="7"><ce:initials>C.G.</ce:initials><ce:indexed-name>Sweep C.G.</ce:indexed-name><ce:surname>Sweep</ce:surname></author><author seq="8"><ce:initials>H.K.</ce:initials><ce:indexed-name>Selbmann H.K.</ce:indexed-name><ce:surname>Selbmann</ce:surname></author><author seq="9"><ce:initials>H.</ce:initials><ce:indexed-name>Graeff H.</ce:indexed-name><ce:surname>Graeff</ce:surname></author><author seq="10"><ce:initials>M.</ce:initials><ce:indexed-name>Schmitt M.</ce:indexed-name><ce:surname>Schmitt</ce:surname></author></ref-authors><ref-sourcetitle>J Natl Cancer Inst</ref-sourcetitle><ref-publicationyear first="2001"/><ref-volisspag><voliss volume="93"/><pagerange first="913" last="920"/></ref-volisspag><ref-text>German NO Study Group</ref-text></ref-info><ref-fulltext>Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M, German NO Study Group (2001) Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 93:913-920</ref-fulltext></reference><reference id="14"><ref-info><ref-title><ref-titletext>Final 10-year analysis of prospective multicenter chemo NO trial for validation of ASCO-recommended biomarkers uPA/PAI-1 for therapy decision making in node-negative breast cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">77950558276</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>N.</ce:initials><ce:indexed-name>Harbeck N.</ce:indexed-name><ce:surname>Harbeck</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Schmitt M.</ce:indexed-name><ce:surname>Schmitt</ce:surname></author><author seq="3"><ce:initials>C.</ce:initials><ce:indexed-name>Meisner C.</ce:indexed-name><ce:surname>Meisner</ce:surname></author><author seq="4"><ce:initials>C.</ce:initials><ce:indexed-name>Friedel C.</ce:indexed-name><ce:surname>Friedel</ce:surname></author><author seq="5"><ce:initials>M.</ce:initials><ce:indexed-name>Untch M.</ce:indexed-name><ce:surname>Untch</ce:surname></author><author seq="6"><ce:initials>M.</ce:initials><ce:indexed-name>Schmidt M.</ce:indexed-name><ce:surname>Schmidt</ce:surname></author><author seq="7"><ce:initials>B.</ce:initials><ce:indexed-name>Lisboa B.</ce:indexed-name><ce:surname>Lisboa</ce:surname></author><author seq="8"><ce:initials>C.</ce:initials><ce:indexed-name>Sweep C.</ce:indexed-name><ce:surname>Sweep</ce:surname></author><author seq="9"><ce:initials>F.</ce:initials><ce:indexed-name>Janicke F.</ce:indexed-name><ce:surname>Jänicke</ce:surname></author><author seq="10"><ce:initials>C.</ce:initials><ce:indexed-name>Thomssen C.</ce:indexed-name><ce:surname>Thomssen</ce:surname></author></ref-authors><ref-sourcetitle>J Clin Oncol</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="27" issue="SUPPL."/><pagerange first="15"/></ref-volisspag><ref-text>Chemo NO Study Group abstr 511</ref-text></ref-info><ref-fulltext>Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M, Lisboa B, Sweep C, Jänicke F, Thomssen C, Chemo NO Study Group (2009) Final 10-year analysis of prospective multicenter Chemo NO trial for validation of ASCO-recommended biomarkers uPA/PAI-1 for therapy decision making in node-negative breast cancer. J Clin Oncol 27:15s (suppl; abstr 511)</ref-fulltext></reference><reference id="15"><ref-info><ref-title><ref-titletext>Prognostic impact of proteolytic factors (uPA, PAI-1, cathepsins B, D, L) in primary breast cancer reflects effects of adjuvant systemic therapy</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0034802806</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>N.</ce:initials><ce:indexed-name>Harbeck N.</ce:indexed-name><ce:surname>Harbeck</ce:surname></author><author seq="2"><ce:initials>U.</ce:initials><ce:indexed-name>Alt U.</ce:indexed-name><ce:surname>Alt</ce:surname></author><author seq="3"><ce:initials>U.</ce:initials><ce:indexed-name>Berger U.</ce:indexed-name><ce:surname>Berger</ce:surname></author><author seq="4"><ce:initials>A.</ce:initials><ce:indexed-name>Kruger A.</ce:indexed-name><ce:surname>Krüger</ce:surname></author><author seq="5"><ce:initials>C.</ce:initials><ce:indexed-name>Thomssen C.</ce:indexed-name><ce:surname>Thomssen</ce:surname></author><author seq="6"><ce:initials>F.</ce:initials><ce:indexed-name>Janicke F.</ce:indexed-name><ce:surname>Jänicke</ce:surname></author><author seq="7"><ce:initials>H.</ce:initials><ce:indexed-name>Hofler H.</ce:indexed-name><ce:surname>Höfler</ce:surname></author><author seq="8"><ce:initials>R.E.</ce:initials><ce:indexed-name>Kates R.E.</ce:indexed-name><ce:surname>Kates</ce:surname></author><author seq="9"><ce:initials>M.</ce:initials><ce:indexed-name>Schmitt M.</ce:indexed-name><ce:surname>Schmitt</ce:surname></author></ref-authors><ref-sourcetitle>Clin Cancer Res</ref-sourcetitle><ref-publicationyear first="2001"/><ref-volisspag><voliss volume="7"/><pagerange first="2757" last="2764"/></ref-volisspag></ref-info><ref-fulltext>Harbeck N, Alt U, Berger U, Krüger A, Thomssen C, Jänicke F, Höfler H, Kates RE, Schmitt M (2001) Prognostic impact of proteolytic factors (uPA, PAI-1, cathepsins B, D, L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin Cancer Res 7:2757-2764</ref-fulltext></reference><reference id="16"><ref-info><ref-title><ref-titletext>Clinical relevance of invasion factors uPA and PAI-1 for individualized therapy decisions in primary breast cancer is greatest when used in combination</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0037083657</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>N.</ce:initials><ce:indexed-name>Harbeck N.</ce:indexed-name><ce:surname>Harbeck</ce:surname></author><author seq="2"><ce:initials>R.</ce:initials><ce:indexed-name>Kates R.</ce:indexed-name><ce:surname>Kates</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Schmitt M.</ce:indexed-name><ce:surname>Schmitt</ce:surname></author></ref-authors><ref-sourcetitle>J Clin Oncol</ref-sourcetitle><ref-publicationyear first="2002"/><ref-volisspag><voliss volume="20" issue="4"/><pagerange first="1000" last="1007"/></ref-volisspag></ref-info><ref-fulltext>Harbeck N, Kates R, Schmitt M (2002) Clinical relevance of invasion factors uPA and PAI-1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 20(4): 1000-1007</ref-fulltext></reference><reference id="17"><ref-info><ref-title><ref-titletext>Urokinase plasminogen activator in breast cancer analysed in steroid receptors cytosols with a luminometric immunoassay</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0029950191</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Ferno M.</ce:indexed-name><ce:surname>Fernö</ce:surname></author><author seq="2"><ce:initials>P.O.</ce:initials><ce:indexed-name>Bendahl P.O.</ce:indexed-name><ce:surname>Bendahl</ce:surname></author><author seq="3"><ce:initials>A.</ce:initials><ce:indexed-name>Borg A.</ce:indexed-name><ce:surname>Borg</ce:surname></author><author seq="4"><ce:initials>J.</ce:initials><ce:indexed-name>Brundell J.</ce:indexed-name><ce:surname>Brundell</ce:surname></author><author seq="5"><ce:initials>L.</ce:initials><ce:indexed-name>Hirschberg L.</ce:indexed-name><ce:surname>Hirschberg</ce:surname></author><author seq="6"><ce:initials>H.</ce:initials><ce:indexed-name>Olsson H.</ce:indexed-name><ce:surname>Olsson</ce:surname></author><author seq="7"><ce:initials>D.</ce:initials><ce:indexed-name>Killander D.</ce:indexed-name><ce:surname>Killander</ce:surname></author></ref-authors><ref-sourcetitle>Eur J Cancer</ref-sourcetitle><ref-publicationyear first="1996"/><ref-volisspag><voliss volume="32 A"/><pagerange first="793" last="801"/></ref-volisspag></ref-info><ref-fulltext>Fernö M, Bendahl PO, Borg Å, Brundell J, Hirschberg L, Olsson H, Killander D (1996) Urokinase plasminogen activator in breast cancer, analysed in steroid receptors cytosols with a luminometric immunoassay. Eur J Cancer 32A:793-801</ref-fulltext></reference><reference id="18"><ref-info><ref-title><ref-titletext>Predictive impact of urokinase-type plasminogen activator: Plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">1642475133</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>P.</ce:initials><ce:indexed-name>Manders P.</ce:indexed-name><ce:surname>Manders</ce:surname></author><author seq="2"><ce:initials>V.C.G.</ce:initials><ce:indexed-name>Tjan-Heijnen V.C.G.</ce:indexed-name><ce:surname>Tjan-Heijnen</ce:surname></author><author seq="3"><ce:initials>P.N.</ce:initials><ce:indexed-name>Span P.N.</ce:indexed-name><ce:surname>Span</ce:surname></author><author seq="4"><ce:initials>N.</ce:initials><ce:indexed-name>Grebenchtchikov N.</ce:indexed-name><ce:surname>Grebenchtchikov</ce:surname></author><author seq="5"><ce:initials>J.A.</ce:initials><ce:indexed-name>Foekens J.A.</ce:indexed-name><ce:surname>Foekens</ce:surname></author><author seq="6"><ce:initials>L.V.</ce:initials><ce:indexed-name>Beex L.V.</ce:indexed-name><ce:surname>Beex</ce:surname></author><author seq="7"><ce:initials>C.G.J.</ce:initials><ce:indexed-name>Sweep C.G.J.</ce:indexed-name><ce:surname>Sweep</ce:surname></author></ref-authors><ref-sourcetitle>Cancer Research</ref-sourcetitle><ref-publicationyear first="2004"/><ref-volisspag><voliss volume="64" issue="2"/><pagerange first="659" last="664"/></ref-volisspag><ref-text>DOI 10.1158/0008-5472.CAN-03-1820</ref-text></ref-info><ref-fulltext>Manders P, Tjan-Heijnen VCG, Span PN, Grebenchtchikov N, Geurts-Moespot A, van Tienoven DT, Beex LV, Sweep FC (2004) Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer. Cancer Res 64:659-664 (Pubitemid 38120907)</ref-fulltext></reference><reference id="19"><ref-info><ref-title><ref-titletext>The contribution of molecular markers to the prediction of response in the treatment of breast cancer: A review of the literature on HER-2, p53 and BCL-2</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0033744498</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.</ce:initials><ce:indexed-name>Hamilton A.</ce:indexed-name><ce:surname>Hamilton</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Piccart M.</ce:indexed-name><ce:surname>Piccart</ce:surname></author></ref-authors><ref-sourcetitle>Ann Oncol</ref-sourcetitle><ref-publicationyear first="2000"/><ref-volisspag><voliss volume="11"/><pagerange first="647" last="663"/></ref-volisspag></ref-info><ref-fulltext>Hamilton A, Piccart M (2000) The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. Ann Oncol 11:647-663</ref-fulltext></reference><reference id="20"><ref-info><ref-title><ref-titletext>Enhanced benefit from, adjuvant systemic chemotherapy in breast cancer patients classified high-risk according to urokinasetype plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1)</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0037102368</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>N.</ce:initials><ce:indexed-name>Harbeck N.</ce:indexed-name><ce:surname>Harbeck</ce:surname></author><author seq="2"><ce:initials>R.E.</ce:initials><ce:indexed-name>Kates R.E.</ce:indexed-name><ce:surname>Kates</ce:surname></author><author seq="3"><ce:initials>M.P.</ce:initials><ce:indexed-name>Look M.P.</ce:indexed-name><ce:surname>Look</ce:surname></author><author seq="4"><ce:initials>M.E.</ce:initials><ce:indexed-name>Meijer-Van Gelder M.E.</ce:indexed-name><ce:surname>Meijer-Van Gelder</ce:surname></author><author seq="5"><ce:initials>J.G.</ce:initials><ce:indexed-name>Klijn J.G.</ce:indexed-name><ce:surname>Klijn</ce:surname></author><author seq="6"><ce:initials>A.</ce:initials><ce:indexed-name>Kruger A.</ce:indexed-name><ce:surname>Krüger</ce:surname></author><author seq="7"><ce:initials>M.</ce:initials><ce:indexed-name>Kiechle M.</ce:indexed-name><ce:surname>Kiechle</ce:surname></author><author seq="8"><ce:initials>F.</ce:initials><ce:indexed-name>Janicke F.</ce:indexed-name><ce:surname>Jänicke</ce:surname></author><author seq="9"><ce:initials>M.</ce:initials><ce:indexed-name>Schmitt M.</ce:indexed-name><ce:surname>Schmitt</ce:surname></author><author seq="10"><ce:initials>J.A.</ce:initials><ce:indexed-name>Foekens J.A.</ce:indexed-name><ce:surname>Foekens</ce:surname></author></ref-authors><ref-sourcetitle>Cancer Res</ref-sourcetitle><ref-publicationyear first="2002"/><ref-volisspag><voliss volume="62"/><pagerange first="4617" last="4622"/></ref-volisspag></ref-info><ref-fulltext>Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, Kiechle M, Jänicke F, Schmitt M, Foekens JA (2002) Enhanced benefit from, adjuvant systemic chemotherapy in breast cancer patients classified high-risk according to urokinasetype plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1). Cancer Res 62:4617-4622</ref-fulltext></reference><reference id="21"><ref-info><ref-title><ref-titletext>High levels of uPA and PAI-1 predicts a good response to antracyclines (abstract)</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">77953119996</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Borstnar S.</ce:indexed-name><ce:surname>Borstnar</ce:surname></author><author seq="2"><ce:initials>I.</ce:initials><ce:indexed-name>Vrhovec I.</ce:indexed-name><ce:surname>Vrhovec</ce:surname></author><author seq="3"><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname></author></ref-authors><ref-sourcetitle>Breast Cancer Res Treat</ref-sourcetitle><ref-publicationyear first="2004"/><ref-volisspag><voliss volume="88" issue="SUPPL. 1"/><pagerange first="54" last="55"/></ref-volisspag></ref-info><ref-fulltext>Borstnar S, Vrhovec I, Cufer T (2004) High levels of uPA and PAI-1 predicts a good response to antracyclines (abstract). Breast Cancer Res Treat 88(suppl. 1):54-55</ref-fulltext></reference><reference id="22"><ref-info><ref-title><ref-titletext>Reporting recommendations for tumor marker prognostic studies</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">33644830699</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>L.M.</ce:initials><ce:indexed-name>McShane L.M.</ce:indexed-name><ce:surname>McShane</ce:surname></author><author seq="2"><ce:initials>D.G.</ce:initials><ce:indexed-name>Altman D.G.</ce:indexed-name><ce:surname>Altman</ce:surname></author><author seq="3"><ce:initials>W.</ce:initials><ce:indexed-name>Sauerbrei W.</ce:indexed-name><ce:surname>Sauerbrei</ce:surname></author><author seq="4"><ce:initials>S.E.</ce:initials><ce:indexed-name>Taube S.E.</ce:indexed-name><ce:surname>Taube</ce:surname></author><author seq="5"><ce:initials>M.</ce:initials><ce:indexed-name>Gion M.</ce:indexed-name><ce:surname>Gion</ce:surname></author><author seq="6"><ce:initials>G.M.</ce:initials><ce:indexed-name>Clark G.M.</ce:indexed-name><ce:surname>Clark</ce:surname></author></ref-authors><ref-sourcetitle>J Clin Oncol</ref-sourcetitle><ref-publicationyear first="2005"/><ref-volisspag><voliss volume="23" issue="36"/><pagerange first="9067" last="9072"/></ref-volisspag><ref-text>Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics</ref-text></ref-info><ref-fulltext>McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23(36):9067-9072</ref-fulltext></reference><reference id="23"><ref-info><ref-title><ref-titletext>Grading of invasive carcinoma of the breast</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0001271962</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>C.W.</ce:initials><ce:indexed-name>Elston C.W.</ce:indexed-name><ce:surname>Elston</ce:surname></author></ref-authors><ref-sourcetitle>Diagnostic Histopathology of the Breast</ref-sourcetitle><ref-publicationyear first="1987"/><ref-volisspag><pagerange first="300" last="311"/></ref-volisspag><ref-text>Page DL, Anderson TJ (eds) Churchill Livingstone, Edinburgh</ref-text></ref-info><ref-fulltext>Elston CW (1987) Grading of invasive carcinoma of the breast. In: Page DL, Anderson TJ (eds) Diagnostic histopathology of the breast. Churchill Livingstone, Edinburgh, pp 300-311</ref-fulltext></reference><reference id="24"><ref-info><ref-title><ref-titletext>External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunoabsorbent assay) of urokinase-type plasminogen activator (Upa) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">7844236388</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>C.G.</ce:initials><ce:indexed-name>Sweep C.G.</ce:indexed-name><ce:surname>Sweep</ce:surname></author><author seq="2"><ce:initials>J.</ce:initials><ce:indexed-name>Geurts-Moespot J.</ce:indexed-name><ce:surname>Geurts-Moespot</ce:surname></author><author seq="3"><ce:initials>N.</ce:initials><ce:indexed-name>Grebenschikov N.</ce:indexed-name><ce:surname>Grebenschikov</ce:surname></author><author seq="4"><ce:initials>J.H.</ce:initials><ce:indexed-name>De Witte J.H.</ce:indexed-name><ce:surname>De Witte</ce:surname></author><author seq="5"><ce:initials>J.J.</ce:initials><ce:indexed-name>Heuvel J.J.</ce:indexed-name><ce:surname>Heuvel</ce:surname></author><author seq="6"><ce:initials>M.</ce:initials><ce:indexed-name>Schmitt M.</ce:indexed-name><ce:surname>Schmitt</ce:surname></author><author seq="7"><ce:initials>M.J.</ce:initials><ce:indexed-name>Duffy M.J.</ce:indexed-name><ce:surname>Duffy</ce:surname></author><author seq="8"><ce:initials>F.</ce:initials><ce:indexed-name>Janicke F.</ce:indexed-name><ce:surname>Jänicke</ce:surname></author><author seq="9"><ce:initials>M.D.</ce:initials><ce:indexed-name>Kramer M.D.</ce:indexed-name><ce:surname>Kramer</ce:surname></author><author seq="10"><ce:initials>J.A.</ce:initials><ce:indexed-name>Foekens J.A.</ce:indexed-name><ce:surname>Foekens</ce:surname></author><author seq="11"><ce:initials>N.</ce:initials><ce:indexed-name>Brunner N.</ce:indexed-name><ce:surname>Brünner</ce:surname></author><author seq="12"><ce:initials>G.</ce:initials><ce:indexed-name>Brugal G.</ce:indexed-name><ce:surname>Brugal</ce:surname></author><author seq="13"><ce:initials>A.N.</ce:initials><ce:indexed-name>Pedersen A.N.</ce:indexed-name><ce:surname>Pedersen</ce:surname></author><author seq="14"><ce:initials>T.J.</ce:initials><ce:indexed-name>Benraad T.J.</ce:indexed-name><ce:surname>Benraad</ce:surname></author></ref-authors><ref-sourcetitle>Br J Cancer</ref-sourcetitle><ref-publicationyear first="1998"/><ref-volisspag><voliss volume="78"/><pagerange first="1434" last="1441"/></ref-volisspag></ref-info><ref-fulltext>Sweep CG, Geurts-Moespot J, Grebenschikov N, de Witte JH, Heuvel JJ, Schmitt M, Duffy MJ, Jänicke F, Kramer MD, Foekens JA, Brünner N, Brugal G, Pedersen AN, Benraad TJ (1998) External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunoabsorbent assay) of urokinase-type plasminogen activator (Upa) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br J Cancer 78:1434-1441</ref-fulltext></reference><reference id="25"><ref-info><ref-title><ref-titletext>Comparison of multivariate matching methods: Structures distances, and algorithms</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0003138938</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>X.S.</ce:initials><ce:indexed-name>Gu X.S.</ce:indexed-name><ce:surname>Gu</ce:surname></author><author seq="2"><ce:initials>P.R.</ce:initials><ce:indexed-name>Rosenbaum P.R.</ce:indexed-name><ce:surname>Rosenbaum</ce:surname></author></ref-authors><ref-sourcetitle>J Comput Graph Stat</ref-sourcetitle><ref-publicationyear first="1993"/><ref-volisspag><voliss volume="2" issue="4"/><pagerange first="405" last="420"/></ref-volisspag></ref-info><ref-fulltext>Gu XS, Rosenbaum PR (1993) Comparison of multivariate matching methods: structures, distances, and algorithms. J Comput Graph Stat 2(4):405-420</ref-fulltext></reference><reference id="26"><ref-info><ref-title><ref-titletext>UPA and PAI1 in breast cancer: Review of their clinical utility and current validation in the prospective NNBC-3 trial</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">38649095227</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>K.</ce:initials><ce:indexed-name>Annecke K.</ce:indexed-name><ce:surname>Annecke</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Schmitt M.</ce:indexed-name><ce:surname>Schmitt</ce:surname></author><author seq="3"><ce:initials>U.</ce:initials><ce:indexed-name>Euler U.</ce:indexed-name><ce:surname>Euler</ce:surname></author><author seq="4"><ce:initials>M.</ce:initials><ce:indexed-name>Zerm M.</ce:indexed-name><ce:surname>Zerm</ce:surname></author><author seq="5"><ce:initials>D.</ce:initials><ce:indexed-name>Paepke D.</ce:indexed-name><ce:surname>Paepke</ce:surname></author><author seq="6"><ce:initials>S.</ce:initials><ce:indexed-name>Paepke S.</ce:indexed-name><ce:surname>Paepke</ce:surname></author><author seq="7"><ce:initials>G.</ce:initials><ce:indexed-name>Von Minckwitz G.</ce:indexed-name><ce:surname>Von Minckwitz</ce:surname></author><author seq="8"><ce:initials>C.</ce:initials><ce:indexed-name>Thomssen C.</ce:indexed-name><ce:surname>Thomssen</ce:surname></author><author seq="9"><ce:initials>N.</ce:initials><ce:indexed-name>Harbeck N.</ce:indexed-name><ce:surname>Harbeck</ce:surname></author></ref-authors><ref-sourcetitle>Adv Clin Chem</ref-sourcetitle><ref-publicationyear first="2008"/><ref-volisspag><voliss volume="45"/><pagerange first="31" last="45"/></ref-volisspag></ref-info><ref-fulltext>Annecke K, Schmitt M, Euler U, Zerm M, Paepke D, Paepke S, von Minckwitz G, Thomssen C, Harbeck N (2008) uPA and PAI1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem 45:31-45</ref-fulltext></reference><reference id="27"><ref-info><ref-title><ref-titletext>Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84871470577</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.S.</ce:initials><ce:indexed-name>Knoop A.S.</ce:indexed-name><ce:surname>Knoop</ce:surname></author><author seq="2"><ce:initials>H.</ce:initials><ce:indexed-name>Knudsen H.</ce:indexed-name><ce:surname>Knudsen</ce:surname></author><author seq="3"><ce:initials>E.</ce:initials><ce:indexed-name>Balslev E.</ce:indexed-name><ce:surname>Balslev</ce:surname></author><author seq="4"><ce:initials>B.B.</ce:initials><ce:indexed-name>Rasmussen B.B.</ce:indexed-name><ce:surname>Rasmussen</ce:surname></author><author seq="5"><ce:initials>J.</ce:initials><ce:indexed-name>Overgaard J.</ce:indexed-name><ce:surname>Overgaard</ce:surname></author><author seq="6"><ce:initials>K.V.</ce:initials><ce:indexed-name>Nielsen K.V.</ce:indexed-name><ce:surname>Nielsen</ce:surname></author><author seq="7"><ce:initials>A.</ce:initials><ce:indexed-name>Schonau A.</ce:indexed-name><ce:surname>Schonau</ce:surname></author><author seq="8"><ce:initials>K.</ce:initials><ce:indexed-name>Gunnarsdottir K.</ce:indexed-name><ce:surname>Gunnarsdóttir</ce:surname></author><author seq="9"><ce:initials>K.E.</ce:initials><ce:indexed-name>Olsen K.E.</ce:indexed-name><ce:surname>Olsen</ce:surname></author><author seq="10"><ce:initials>H.</ce:initials><ce:indexed-name>Mouridsen H.</ce:indexed-name><ce:surname>Mouridsen</ce:surname></author><author seq="11"><ce:initials>B.</ce:initials><ce:indexed-name>Ejlertsen B.</ce:indexed-name><ce:surname>Ejlertsen</ce:surname></author></ref-authors><ref-sourcetitle>J Clin Oncol</ref-sourcetitle><ref-publicationyear first="2006"/><ref-volisspag><voliss volume="24" issue="6"/><pagerange first="1015"/></ref-volisspag><ref-text>Danish Breast Cancer Cooperative Group</ref-text></ref-info><ref-fulltext>Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, Schonau A, Gunnarsdóttir K, Olsen KE, Mouridsen H, Ejlertsen B, Danish Breast Cancer Cooperative Group (2006) Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 24(6): 1015</ref-fulltext></reference><reference id="28"><ref-info><refd-itemidlist><itemid idtype="SGR">77953123071</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Ravnik M.</ce:indexed-name><ce:surname>Ravnik</ce:surname></author><author seq="2"><ce:initials>I.</ce:initials><ce:indexed-name>Takac I.</ce:indexed-name><ce:surname>Takac</ce:surname></author><author seq="3"><ce:initials>D.</ce:initials><ce:indexed-name>Arko D.</ce:indexed-name><ce:surname>Arko</ce:surname></author><author seq="4"><ce:initials>B.</ce:initials><ce:indexed-name>Gorisek B.</ce:indexed-name><ce:surname>Gorisek</ce:surname></author><author seq="5"><ce:initials>N.</ce:initials><ce:indexed-name>Cas-Sikosek N.</ce:indexed-name><ce:surname>Cas-Sikosek</ce:surname></author><author seq="6"><ce:initials>M.</ce:initials><ce:indexed-name>Lampelj M.</ce:indexed-name><ce:surname>Lampelj</ce:surname></author><author seq="7"><ce:initials>J.</ce:initials><ce:indexed-name>Ravnik J.</ce:indexed-name><ce:surname>Ravnik</ce:surname></author><author seq="8"><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname></author></ref-authors><ref-sourcetitle>Correlation between Invasive Markers (UPA/PAI-1) and HER-2 Status in Early Breast Cancer</ref-sourcetitle><ref-publicationyear first="2007"/><ref-volisspag><pagerange first="81"/></ref-volisspag><ref-text>Samija M (ed). 5th Central European oncology congress, Opatija, Croatia, June 20-23. Final program &amp; abstract book: Croatian Oncological Society</ref-text></ref-info><ref-fulltext>Ravnik M, Takac I, Arko D, Gorisek B, Cas-Sikosek N, Lampelj M, Ravnik J, Cufer T (2007) Correlation between invasive markers (uPA/PAI-1) and HER-2 status in early breast cancer. In: Samija M (ed). 5th Central European oncology congress, Opatija, Croatia, June 20-23. Final program &amp; abstract book: Croatian Oncological Society, p 81</ref-fulltext></reference><reference id="29"><ref-info><ref-title><ref-titletext>Limited prognostic value of c-erbB-2 compared to uPA and PAI-1 in primary breast carcinoma</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0141989949</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>C.</ce:initials><ce:indexed-name>Bouchet C.</ce:indexed-name><ce:surname>Bouchet</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Ferrero-Pous M.</ce:indexed-name><ce:surname>Ferrero-Pous</ce:surname></author><author seq="3"><ce:initials>K.</ce:initials><ce:indexed-name>Hacene K.</ce:indexed-name><ce:surname>Hacene</ce:surname></author><author seq="4"><ce:initials>V.</ce:initials><ce:indexed-name>Becette V.</ce:indexed-name><ce:surname>Becette</ce:surname></author><author seq="5"><ce:initials>F.</ce:initials><ce:indexed-name>Spyratos F.</ce:indexed-name><ce:surname>Spyratos</ce:surname></author></ref-authors><ref-sourcetitle>International Journal of Biological Markers</ref-sourcetitle><ref-publicationyear first="2003"/><ref-volisspag><voliss volume="18" issue="3"/><pagerange first="207" last="217"/></ref-volisspag></ref-info><ref-fulltext>Bouchet C, Ferrero-Poüs M, Hacene K, Becette V, Spyratos F (2003) Limited prognostic value of c-erbB-2 compared to uPA and PAI-1 in primary breast carcinoma. Int J Biol Markers 18(3): 207-217 (Pubitemid 37254287)</ref-fulltext></reference><reference id="30"><ref-info><ref-title><ref-titletext>Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">33748988736</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>P.</ce:initials><ce:indexed-name>Urban P.</ce:indexed-name><ce:surname>Urban</ce:surname></author><author seq="2"><ce:initials>V.</ce:initials><ce:indexed-name>Vuaroqueaux V.</ce:indexed-name><ce:surname>Vuaroqueaux</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Labuhn M.</ce:indexed-name><ce:surname>Labuhn</ce:surname></author><author seq="4"><ce:initials>M.</ce:initials><ce:indexed-name>Delorenzi M.</ce:indexed-name><ce:surname>Delorenzi</ce:surname></author><author seq="5"><ce:initials>P.</ce:initials><ce:indexed-name>Wirapati P.</ce:indexed-name><ce:surname>Wirapati</ce:surname></author><author seq="6"><ce:initials>E.</ce:initials><ce:indexed-name>Wight E.</ce:indexed-name><ce:surname>Wight</ce:surname></author><author seq="7"><ce:initials>H.-J.</ce:initials><ce:indexed-name>Senn H.-J.</ce:indexed-name><ce:surname>Senn</ce:surname></author><author seq="8"><ce:initials>C.</ce:initials><ce:indexed-name>Benz C.</ce:indexed-name><ce:surname>Benz</ce:surname></author><author seq="9"><ce:initials>U.</ce:initials><ce:indexed-name>Eppenberger U.</ce:indexed-name><ce:surname>Eppenberger</ce:surname></author><author seq="10"><ce:initials>S.</ce:initials><ce:indexed-name>Eppenberger-Castori S.</ce:indexed-name><ce:surname>Eppenberger-Castori</ce:surname></author></ref-authors><ref-sourcetitle>Journal of Clinical Oncology</ref-sourcetitle><ref-publicationyear first="2006"/><ref-volisspag><voliss volume="24" issue="26"/><pagerange first="4245" last="4253"/></ref-volisspag><ref-text>DOI 10.1200/JCO.2005.05.1912</ref-text></ref-info><ref-fulltext>Urban P, Vuaroqueaux V, Labuhn M, Delorenzi M, Wirapati P, Wight E, Senn HJ, Benz C, Eppenberger U, Eppenberger-Castori S (2006) Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer. J Clin Oncol 24(26):4245-4253 (Pubitemid 46630781)</ref-fulltext></reference><reference id="31"><ref-info><ref-title><ref-titletext>HER-2/neu gene amplification determined by in-situ hybridization (FISH) allows risk group assessment in node-negative breast cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0033109529</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>N.</ce:initials><ce:indexed-name>Harbeck N.</ce:indexed-name><ce:surname>Harbeck</ce:surname></author><author seq="2"><ce:initials>J.</ce:initials><ce:indexed-name>Ross J.</ce:indexed-name><ce:surname>Ross</ce:surname></author><author seq="3"><ce:initials>S.</ce:initials><ce:indexed-name>Yurdseven S.</ce:indexed-name><ce:surname>Yurdseven</ce:surname></author><author seq="4"><ce:initials>P.</ce:initials><ce:indexed-name>Dettmar P.</ce:indexed-name><ce:surname>Dettmar</ce:surname></author><author seq="5"><ce:initials>M.</ce:initials><ce:indexed-name>Polcher M.</ce:indexed-name><ce:surname>Pölcher</ce:surname></author><author seq="6"><ce:initials>W.</ce:initials><ce:indexed-name>Kuhn W.</ce:indexed-name><ce:surname>Kuhn</ce:surname></author><author seq="7"><ce:initials>K.</ce:initials><ce:indexed-name>Ulm K.</ce:indexed-name><ce:surname>Ulm</ce:surname></author><author seq="8"><ce:initials>H.</ce:initials><ce:indexed-name>Graeff H.</ce:indexed-name><ce:surname>Graeff</ce:surname></author><author seq="9"><ce:initials>M.</ce:initials><ce:indexed-name>Schmitt M.</ce:indexed-name><ce:surname>Schmitt</ce:surname></author></ref-authors><ref-sourcetitle>Int J Oncol</ref-sourcetitle><ref-publicationyear first="1999"/><ref-volisspag><voliss volume="14"/><pagerange first="663" last="671"/></ref-volisspag></ref-info><ref-fulltext>Harbeck N, Ross J, Yurdseven S, Dettmar P, Pölcher M, Kuhn W, Ulm K, Graeff H, Schmitt M (1999) HER-2/neu gene amplification determined by in-situ hybridization (FISH) allows risk group assessment in node-negative breast cancer. Int J Oncol 14:663-671</ref-fulltext></reference><reference id="32"><ref-info><ref-title><ref-titletext>HER-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0034886716</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>G.</ce:initials><ce:indexed-name>Konecny G.</ce:indexed-name><ce:surname>Konecny</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Untch M.</ce:indexed-name><ce:surname>Untch</ce:surname></author><author seq="3"><ce:initials>J.</ce:initials><ce:indexed-name>Arboleda J.</ce:indexed-name><ce:surname>Arboleda</ce:surname></author><author seq="4"><ce:initials>C.</ce:initials><ce:indexed-name>Wilson C.</ce:indexed-name><ce:surname>Wilson</ce:surname></author><author seq="5"><ce:initials>S.</ce:initials><ce:indexed-name>Kahlert S.</ce:indexed-name><ce:surname>Kahlert</ce:surname></author><author seq="6"><ce:initials>B.</ce:initials><ce:indexed-name>Boettcher B.</ce:indexed-name><ce:surname>Boettcher</ce:surname></author><author seq="7"><ce:initials>M.</ce:initials><ce:indexed-name>Felber M.</ce:indexed-name><ce:surname>Felber</ce:surname></author><author seq="8"><ce:initials>M.</ce:initials><ce:indexed-name>Beryt M.</ce:indexed-name><ce:surname>Beryt</ce:surname></author><author seq="9"><ce:initials>S.</ce:initials><ce:indexed-name>Lude S.</ce:indexed-name><ce:surname>Lude</ce:surname></author><author seq="10"><ce:initials>H.</ce:initials><ce:indexed-name>Hepp H.</ce:indexed-name><ce:surname>Hepp</ce:surname></author><author seq="11"><ce:initials>D.</ce:initials><ce:indexed-name>Slamon D.</ce:indexed-name><ce:surname>Slamon</ce:surname></author><author seq="12"><ce:initials>M.</ce:initials><ce:indexed-name>Pegram M.</ce:indexed-name><ce:surname>Pegram</ce:surname></author></ref-authors><ref-sourcetitle>Clinical Cancer Research</ref-sourcetitle><ref-publicationyear first="2001"/><ref-volisspag><voliss volume="7" issue="8"/><pagerange first="2448" last="2457"/></ref-volisspag></ref-info><ref-fulltext>Konecny G, Untch M, Arboleda J, Wilson C, Kahlert S, Boettcher B, Felber M, Beryt M, Lude S, Hepp H, Slamon D, Pegram M (2001) HER-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. Clin Cancer Res 7:2448-2457 (Pubitemid 32751648)</ref-fulltext></reference><reference id="33"><ref-info><ref-title><ref-titletext>Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0037445194</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>I.</ce:initials><ce:indexed-name>Zemzoum I.</ce:indexed-name><ce:surname>Zemzoum</ce:surname></author><author seq="2"><ce:initials>R.E.</ce:initials><ce:indexed-name>Kates R.E.</ce:indexed-name><ce:surname>Kates</ce:surname></author><author seq="3"><ce:initials>J.S.</ce:initials><ce:indexed-name>Ross J.S.</ce:indexed-name><ce:surname>Ross</ce:surname></author><author seq="4"><ce:initials>P.</ce:initials><ce:indexed-name>Dettmar P.</ce:indexed-name><ce:surname>Dettmar</ce:surname></author><author seq="5"><ce:initials>M.</ce:initials><ce:indexed-name>Dutta M.</ce:indexed-name><ce:surname>Dutta</ce:surname></author><author seq="6"><ce:initials>C.</ce:initials><ce:indexed-name>Henrichs C.</ce:indexed-name><ce:surname>Henrichs</ce:surname></author><author seq="7"><ce:initials>S.</ce:initials><ce:indexed-name>Yurdseven S.</ce:indexed-name><ce:surname>Yurdseven</ce:surname></author><author seq="8"><ce:initials>H.</ce:initials><ce:indexed-name>Hofler H.</ce:indexed-name><ce:surname>Hofler</ce:surname></author><author seq="9"><ce:initials>M.</ce:initials><ce:indexed-name>Kiechle M.</ce:indexed-name><ce:surname>Kiechle</ce:surname></author><author seq="10"><ce:initials>M.</ce:initials><ce:indexed-name>Schmitt M.</ce:indexed-name><ce:surname>Schmitt</ce:surname></author><author seq="11"><ce:initials>N.</ce:initials><ce:indexed-name>Harbeck N.</ce:indexed-name><ce:surname>Harbeck</ce:surname></author></ref-authors><ref-sourcetitle>Journal of Clinical Oncology</ref-sourcetitle><ref-publicationyear first="2003"/><ref-volisspag><voliss volume="21" issue="6"/><pagerange first="1022" last="1028"/></ref-volisspag><ref-text>DOI 10.1200/JCO.2003.04.170</ref-text></ref-info><ref-fulltext>Zemzoum I, Kates RE, Ross JS, Dettmar P, Dutta M, Henrichs C, Yurdseven S, Höfler H, Kiechle M, Schmitt M, Harbeck N (2003) Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patients outcome in node-negative breast cancer. J Clin Oncol 21(6):1022-1028 (Pubitemid 46594130)</ref-fulltext></reference></bibliography></tail></bibrecord></item></abstracts-retrieval-response>